Product Risk Warning：

Investment involves risks, including the loss of principle. Past performance is not indicative of future results. Before investing in below products, investor should refer to the Fund's prospectus for details, including the risk factors. You should not make investment decision based on the information on this material alone. Please note:

Important Information about ChinaAMC Direxion CSI 300 Index Daily (2x) Leveraged Product/ChinaAMC Direxion CSI 300 Index Daily (-1x) Inverse Product:

• ChinaAMC Direxion CSI 300 Index Daily (2x) Leveraged Product/ChinaAMC Direxion CSI 300 Index Daily (-1x) Inverse Product (collectively, “Products”) are swaps-based leveraged/inverse products and are not suitable for all investors. The Products only target sophisticated trading-oriented investors who understand the potential consequences of seeking daily leveraged / inverse results and the associated risks and constantly monitor the performance of their holdings on a daily basis.
• The Products seeks to obtain the required exposure through swaps with different swap counterparties. The Products aim to provide daily investment results, before fees and expenses, which closely correspond to the leveraged (2x) / inverse (-1x) daily performance of the CSI 300 Index (the “Index”).
• The Products do not seek to achieve their stated investment objectives over a period of time greater than one day.
• The Products are not intended for holding longer than one day as the performance of the Products over a longer period may deviate from and be uncorrelated to the leveraged/inverse performance of the Index over the period (e.g. the loss may be more than 2 times the decrease in the Index/-1 time the increase in the Index). The Products are designed to be used for short term trading or hedging purposes, and are not intended for long term investment.
• Investing in the leveraged product is subject to the general market risk of equity investment, its value will be fluctuated because of multiple factors, and both gains and losses will be magnified. Investing in the inverse products is different from taking a short position. Because of daily rebalancing, the return profile of the inverse products is not the same as that of a short position. Risk investment outcomes of the inverse products are the opposite of conventional investment funds. If the value of the Index increases for extended periods, the inverse products will likely lose most or all of their values.
• The Products also involve synthetic replication and counterparty risk, settlement risk, default risk, market risk, price movements risk, intraday counterparty risk, risk of increase in swap fees and early termination of swaps, derivative instrument investment risk, leveraged/inverse performance risk, risk of rebalancing activities, liquidity risk, intraday investment risk, currency risk, concentration risk, PRC market risk, risk of investment in debt securities and other funds, PRC tax risk, passive investment risk, trading risk, reliance on market maker risk, tracking error and correlation risk, volatility risk and termination risk.
• Swap counterparties of the Products may have daily capacity limits, when the limits are reached, the Products’ ability to adjust the size of swaps for sufficient exposure to achieve their investment objectives may be adversely affected.
• Investment involves risks. Past performance is not indicative of future results, future returns are not guaranteed. Investors may be subject to substantial losses, and a loss of original capital may occur. Investors should not make any investment decision solely based on the information on this presentation alone. Please read the relevant offering documents for details including the risk factors (for example, the Products may be terminated in advance under certain circumstances) before making any investment decisions. If necessary, you should seek independent professional advice.

Important Information about ChinaAMC CSI 300 Index ETF

• The Fund aims to provide investment result that, before fees and expenses, closely corresponds to the performance of the CSI 300 Index (the "Index"). The Fund invests in the PRC's securities market through the RQFII investment quota granted to the Manager and the Stock Connect.
• The Fund is subject to concentration risk as a result of tracking the performance of a single geographical region (the PRC) and may likely be more volatile than a broad-based fund.
• The Fund is subject to risks relating to the RQFII regime, such as default in execution or settlement of transaction by a PRC broker or the PRC Custodian, change of RQFII policy and rules and uncertainty to their implementation, repatriation restrictions and insufficient RQFII quota to the Fund.
• The Fund is subject to risks associated with the Stock Connect, such as change of relevant rules and regulations, quota limitations, suspension of the Stock Connect programme. In the event that the Fund’s ability to invest in A-Shares through the Stock Connect on a timely basis is adversely affected, the Manager can only rely on RQFII investments to achieve the Fund’s investment objective.
• Investing in emerging markets, such as the PRC, involves a greater risk such as greater political, tax, economic, foreign exchange, liquidity and regulatory risks.
• If there is a suspension of the inter-counter transfer of units between the HKD counter and the RMB counter, the unitholders will only be able to trade their units in the relevant counter on the SEHK. The market price on the SEHK of units traded in HKD and of units traded in RMB may deviate significantly due to different factors, such as market liquidity, supply and demand in each counter and the exchange rate between the RMB and HKD (in both the onshore and the offshore markets). As such investors may pay more or receive less when buying units traded in HKD on the SEHK than in respect of units traded in RMB and vice versa. Investors without RMB accounts may buy and sell HKD traded units only. Such investors should note that distributions are made in RMB only and they may suffer a foreign exchange loss and incur foreign exchange associated fees and charges to receive their dividend. Not all brokers and CCASS participants may be familiar with and able to buy units in one counter and to sell units in the other or to carry out inter-counter transfers of units or to trade both counters at the same time. This may inhibit or delay an investor dealing in both HKD traded units and RMB traded units and may mean the investor can only trade in one currency.
• As the SSE and the SZSE may be open when units in the Fund are not priced, the value of the securities in Fund’s portfolio may change on days when investors will not be able to purchase or sell the Fund’s units. Differences in trading hours between the SSE and the SZSE, and the SEHK and A-Shares’ trading bands may increase the level of premium/discount of the unit price to its NAV.
• The Fund is denominated in RMB. RMB is currently not freely convertible and is subject to exchange controls and restrictions. A non-RMB based investors in units are exposed to foreign exchange risk. There is no guarantee that the value of RMB against the investors' base currencies (for example HKD) will not depreciate.
• The Fund is not "actively managed" and therefore, when there is a decline in the Index, the Fund will also decrease in value. The Manager will not take defensive position in declining markets. Investors may lose a significant part or all of their respective investments if the Index falls.
• Generally, retail investors can only buy or sell units of the Fund on the SEHK. The trading price of the units on the SEHK is driven by market factors such as the demand and supply of the units. Therefore, the units may trade at a substantial premium or discount to the Fund's NAV.

Important Information about ChinaAMC Direxion NASDAQ-100 Index Daily Leveraged / Inverse Product and Hang Seng Index Daily Leveraged / Inverse Products:

• ChinaAMC Direxion Hang Seng Index Daily (2x) Leveraged Product / ChinaAMC Direxion Hang Seng Index Daily (-1x) Inverse Product (“Hang Seng Index Products”), ChinaAMC Direxion NASDAQ-100 Index Daily (2x) Leveraged Product / ChinaAMC Direxion Nasdaq-100 Index Daily (-1x) Inverse Product. ChinaAMC Direxion Nasdaq-100 Index Daily (-2x) Inverse Product ( “Nasdaq-100 Index Products”), (collectively, “Products”) are futures-based leveraged/inverse products and are not suitable for all investors. The Products only target sophisticated trading-oriented investors who understand the potential consequences of seeking daily leveraged/inverse results and the associated risks and constantly monitor the performance of their holdings on a daily basis.
• Hang Seng Index Products invest directly in Hang Seng Index futures contracts (“HSI Futures”) which are traded on the Hong Kong Futures Exchange Limited (the “HKFE”). Hang Seng Index Products aim to provide daily investment results, before fees and expenses, which closely correspond to leveraged (2x) / inverse (-1x) of the daily performance of the Hang Seng Index (the “Hang Seng Index”).
• Nasdaq-100 Index Products invest directly in E-mini NASDAQ 100 Futures (“Nasdaq-100 Futures”) which are traded on the Chicago Mercantile Exchange (the “CME”). Nasdaq-100 Index Products aim to provide daily investment results, before fees and expenses, which closely correspond to leveraged (2x) / inverse (-1x)/inverse (-2x) of the daily performance of the Nadsaq-100 Index (the “Nasdaq-100 Index”).
• The Product does not seek to achieve its stated investment objective over a period of time greater than one day.
• The Products are not intended for holding longer than one day as the performance of the Products over a longer period may deviate from and be uncorrelated to the leveraged/inverse performance of the relevant index over the period (e.g. the loss may be more than 2 times the decrease in the Index/-1 time the increase in the Index /-2 times the increase in the Index). The Products are designed to be used for short term trading or hedging purposes, and are not intended for long term investment.
• Investing in the leveraged product is subject to the general market risk of equity investment, its value will be fluctuated because of multiple factors. Investing in the inverse products is different from taking a short position. Because of rebalancing, the return profile of the inverse products is not the same as that of a short position. Risk investment outcome of the Inverse Product is the opposite of conventional investment funds. If the value of the Index increases for extended periods, the Inverse Product will likely lose most or all of its value.
• The Products involve futures contracts risk, leveraged/inverse performance risk, risk of rebalancing activities, volatility risk, liquidity risk, intraday investment risk, portfolio turnover risk, concentration risk, US markets risk, Nasdaq-100 constituents risk, passive investment risk, reliance on the investment adviser risk, difference in price limit risk, trading time differences risk, trading risk, reliance on market maker risk, tracking error and correlation risk, termination risk, other currency distributions risk and currency risk.
• Investment involves risks. Past performance is not indicative of future results, future returns are not guaranteed. Investor may be subject to substantial losses, and a loss of original capital may occur. Investor should not make any investment decision solely based on the information on this presentation alone. Please read the relevant offering documents for details including the risk factors before making any investment decisions. If necessary, you should seek independent professional advice.